STAT+: Hope for Kendall Square’s lab market

- STAT+: Kendall Square’s lab market heats up, but the real signal is in the data. Sanofi halts riliprubart’s Phase 3 trial—another hit to R&D pipelines, reminding us that biology remains stubbornly analog. Meanwhile, Parabilis Medicines bags a record $670M IPO, proving capital still flows to oncology innovation. Across Europe, drug-pricing tensions mount as aging demographics clash with U.S. cost demands. Yet, beneath the political friction lies a digital imperative: health AI and diagnostic tech are becoming the only scalable levers for efficiency. As trials grow more complex, the need for robust digital infrastructure to manage data integrity and trial logistics is no longer optional—it’s the backbone of modern biotech. For those tracking the intersection of science and silicon, the story isn’t just about molecules; it’s about the algorithms and systems that bring them to life.